Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 9 - You Need To See This

Pfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for Income

Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options.

Pfizer Stock: Analyst Estimates & Ratings

Pfizer Stock: Analyst Estimates & Ratings

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills

Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, highlighting real-time data integration and pinpoint analytics that would make Pharma RD from the past look like it’s still sending lab results by fax. Down the…

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000'

Investor sentiment around several major stocks got a boost this week thanks to upbeat commentary from Jim Cramer and fresh analyst support.

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside

Under the Radar: Hidden Value Across the Atlantic – 3 Stocks to Watch

Here is what they are not talking about on CNBC right now.

inkl

Read news from The Economist, FT, and more,
with one subscription

Trade stand-off continues as US drug tariffs loom

Trade stand-off continues as US drug tariffs loom

The deadline on US pharmaceutical tariffs has been dramatically brought forward, in the latest escalation of Donald Trump's trade war with the world.

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Retirement Ready: 3 Dividend Stocks to Set and Forget

Retirement Ready: 3 Dividend Stocks to Set and Forget

These are three rock-solid dividend stocks you can buy now and confidently forget, knowing they’ll keep working for you year after year.

Don’t Miss These 4 Stocks With Explosive Dividend Yields

Don’t Miss These 4 Stocks With Explosive Dividend Yields

See which large-cap U.S. stocks offer the highest yields in healthcare, materials, utilities, and real estate. Their yields range from 6% to over 14%.

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, can cause cancer.

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence (BCR) at high…

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Get all your
news in one place.

100's of premium titles.
One news app.

Wednesday’s Unusual Options Activity Reveals 3 Standout Long Straddle Plays

There were 37 unusually active options in Wednesday Trading that expire in 30 days. This DTE reveals three standout long straddle plays that provide a nice combination of time and cost, while allowing increased volatility to take its course.

The Independent UK

Ursula von der Leyen faces confidence vote in far-right challenge

A range of accusations have been levelled against the European Commission president

The Guardian - UK

Von der Leyen survives censure vote but faces calls to reverse EU’s rightward drift

Debate on motion against European Commission president lifts lid on simmering discontent among MEPs

Pfizer Earnings Preview: What to Expect

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company’s bottom-line figure.

Get all your
news in one place.

100's of premium titles.
One news app.

Top 5 Undervalued Dividend Stocks With Strong Payout Potential

Seemingly undervalued dividend stocks, such as BAC, F, MO, VZ, and PFE, offer a rare combination of strong yields and attractive valuations.

Evening Standard

Regulator warns of small risk of serious condition in people having RSV jab

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The Conversation

Turbulent research landscape imperils US brain gain − and ultimately American prosperity

Despite representing only 4% of the world’s population, the United States accounts for over half of science Nobel Prizes awarded since 2000, hosts seven of The Times Higher Education Top 10 science universities, and incubates firms such as Alphabet (Google), Meta and Pfizer that turn federally funded discoveries into billion-dollar…

Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year historical average P/E ratio.

International Business Times UK

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines.

MEPs seek Commission President von der Leyen's resignation with censure motion

Supporters of a motion of censure against Commission President Ursula von der Leyen hope it will put enough political pressure on her leadership to force a resignation – mirroring the 1999 downfall of Commission President Jacques Santer.

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

1 … 8 9 10 11

People

185,528 stories

Robert F. Kennedy Jr

Ursula von der Leyen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Supreme Court

European Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prostate Cancer

Places

367,631 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play